Volume 8, Issue 1, February 2020, Page: 20-24
Assessment of the Risk of Hemochromatosis in Polytransfused Sickle Cell Patients at the Abidjan Transfusion Therapy Unit
Yassongui Mamadou Sekongo, Department of Training and Research, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Kabore Saydou, Laboratory of quality control, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Kouakou Boidy, Hematology Department, Training and Research Unit of Medical Sciences, Abidjan, Côte D’Ivoire
Kouamenan Sidonie, Hemovigilance Service, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Kassogue Kadidja, Transfusion Therapy Unit, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
N’Guessan Parfait, Transfusion Therapy Unit, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Oue Nabo Bertin, Transfusion Therapy Unit, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Konate Seidou, General Direction, National Blood Transfusion Center, Abidjan, Côte D’Ivoire
Sanogo Ibrahima, Hematology Service, Teaching Hospital Center of Yopogon, Abidjan, Côte D’Ivoire
Received: Jan. 15, 2020;       Accepted: Jan. 27, 2020;       Published: Feb. 7, 2020
DOI: 10.11648/j.ajbls.20200801.15      View  15      Downloads  59
Abstract
In Côte d'Ivoire, sickle cell disease affects 14% of the population. It is responsible for significant morbidity and mortality. Transfusion is a significant element in the management of major sickle cell anemia, which exposes them to post-transfusion hemochromatosis. The biological diagnosis is based on the determination of serum iron and the transferrin saturation coefficient (CST). As the determination of the CST was not available in our exercise context in Côte d'Ivoire, we determined only the ferritinemia. The interest of this work lies in the therapeutic implication linked to the identification of patients at risk of hemochromatosis because chelators are difficult to access for most patients. This was a prospective, descriptive and analytical study, on polytransfused sickle cell patients, followed at the transfusion therapy unit (UTT) of the CNTS of Abidjan, from 2010 to 2018. We included 78 sickle cell patients, all ages and genders who have received at least ten transfusions. The ferritinemia assay was carried out by ELISA. Transfusion exchange, with 59% of cases, was the most used mode of transfusion. The mean ferritinemia was 1719.19 ng / ml. Hyperferritinemia was found in 63% of patients. Most of the patients were on a long-term transfusion program with an average of 27.5 bags of red blood cell concentrates. Thirty-two patients had received at least 20 bags of red blood cell concentrates. We noted 21 patients treated, including 3 with deferoxamine and 18 treated with oral deferasirox. We have identified 33 sickle cell anemia patients at risk for hemochromatosis. The determinants of the risk of hemochromatosis were the high number of blood bags and the method of transfusion.
Keywords
Hemochromatosis, Sickle Cell Disease, Tranfusion
To cite this article
Yassongui Mamadou Sekongo, Kabore Saydou, Kouakou Boidy, Kouamenan Sidonie, Kassogue Kadidja, N’Guessan Parfait, Oue Nabo Bertin, Konate Seidou, Sanogo Ibrahima, Assessment of the Risk of Hemochromatosis in Polytransfused Sickle Cell Patients at the Abidjan Transfusion Therapy Unit, American Journal of Biomedical and Life Sciences. Vol. 8, No. 1, 2020, pp. 20-24. doi: 10.11648/j.ajbls.20200801.15
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Montalembert (de) M. transfusion in Sickle cell disease In GIROT R., BÉGUÉ P, GALACTÉROS F. eds. The Sickle cell disease. Paris; John Libbey Eurotext 2003: 247–253.
[2]
Marianne de Montaleùbert Therapeitique option in the sickle cell disease. THE PRACTITIONER'S REVIEW / 2004: 54 1558–1567.
[3]
Yawn B. P., Buchanan GR., Afenyi-Annan A. N. et cill. Management of sickle cell disease: summary of the é014 evidence-based report of expert panel members. JAMA, 2014, 312, 1033-1048.
[4]
Piel FB, Steinberg MH, Rees DC. Sick Cell Disease. N Engl J Med 2017; 376: 1561-1573.
[5]
French Federation of Patients Associations with Hemochromatosis. the diagnosis of Hemochromatosis https://www.hemochromatose.org/hemochromatose/le-diagnostic-de-lhemochromatose/.
[6]
Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood. 2008 Apr; 111 (7): 3373–6.
[7]
A Camacho, S Bouhya, P Latry. Posttransfusion hemosiderosis. Transf. Clin. Biol. 2014, 21 (4-5): 273.
[8]
S. Leo-Kodeli, P. Renaudier, B. Lassale. Evaluation of transfusion hemochromatosis prevalence, SFVTT-01 study: Preliminary results of the SFVTT working group. Transf. Clin. Biol. 2014, 21 (4-5): 182–188.
[9]
Elira-Dokekias A, Ngoloet O L, Atipo T, Malanda F, Koko I, Montalembert M. Evaluation of blood transfusion in 112 sickle cell patients homozygous at Brazzaville University Hospital. Transf clin biol 2009; 16 (5-6): 464-70.
[10]
Sangare A, Sanogo I, Meité M, Kple Faget P, Sawadogo S, Segbena A, et al. Contribution to the study of the relationships between sickle cell disease and malaria. Med Afr Noire 1990; 37 (5).
[11]
SangarE A Measures to take in the event of sickle cell disease. Med Prat 1989; 89. P. 2-8.
[12]
De Montalembert M., Tshilolo L. Are therapeutic advances in sickle cell disease applicable in sub-Saharan Africa? Med Trop, 2007, 67, 612-616.
[13]
Sekongo YM. Prevalence of complications and risk factors in major sickle cell disease [Med These]. Abidjan: UFR Medicale Sciences Univ Cocody; 2002, 3051.
[14]
Raouf Hafsia, Fatma Belakhal, Naouel Ben Salah, Emna Gouider, Wijden El Borgi Evaluation of iron overload during sickle cell anemia: about 94 cases. The Tunisie Medicale - 2011; 89 (06): 548 – 552.
[15]
M. Touati, D. Berdessoule, C. Rose. Limousin hematology network (Hematolium) Iron overloads in hemopathies. Latest updated version of 11/22/2012 available on: https://hemato.chu-limoges.fr/hematolim/Portals/0/Reseau%20HEMATOLIM/REF%20HEM%20MAL%2010%20Surcharge%20en%20Fer.pdf.
[16]
Fung EB, Harmatz P, Milet M. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematology 2007; 82: 255-65.
[17]
Harmatz P, Butensky E, Quirolo K. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76-79.
[18]
Davies S, Henthorn JS, Win A. Effect of blood transfusion on iron status in sickle cell anaemia. Clin Lab Haematol 1984; 6: 17-22.
[19]
Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364 (2): 146–56.
[20]
Clara Camaschella, M. D. Treating Iron Overload. The new england journal of medecine. 2013 Juin. 368; 24. R.
Browse journals by subject